Ocuphire Pharma, Inc. Sitemap
- Home
- About
- Product Pipeline
- Clinical Trials
- Overview
- VEGA-2 Pivotal Phase 3 Trial of Nyxol® in Presbyopia
- ZETA-1: Diabetic Retinopathy Phase 2 Clinical Trial for APX3330
- MIRA-4: Nyxol (0.75% Phentolamine Ophthalmic Solution) to Reverse Pharmacologically-Induced Mydriasis in Pediatric Subjects
- MIRA-3
- MIRA-2: Reversal of Mydriasis Phase 3 Clinical Trial for Nyxol
- LYNX-1: Dim Light Vision Disturbance Phase 3 Clinical Trial for Nyxol
- VEGA-1: Presbyopia Phase 2 Clinical Trial for Nyxol with Low-Dose Pilocarpine
- Partnerships
- News & Media
- Investors
- Contact
- Careers
- Privacy Policy
- Disclaimer
- Sitemap
- Terms of Use